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Background: Dengue virus (DENV), a member of the family Flaviviridae, is at present the most widespread
causative agent of a human viral disease transmitted by mosquitoes. Despite the increasing incidence of this
pathogen, there are no antiviral drugs or vaccines currently available for treatment or prevention. In a previous
screening assay, we identified a group of N-allyl acridones as effective virus inhibitors. Here, the antiviral activity
and mode of action targeted to viral RNA replication of one of the most active DENV-2 inhibitors was further
characterized.
Results: The compound 10-allyl-7-chloro-9(10H)-acridone, designated 3b, was active to inhibit the in vitro
infection of Vero cells with the four DENV serotypes, with effective concentration 50% (EC50) values in the range
12.5-27.1 μM, as determined by virus yield inhibition assays. The compound was also effective in human HeLa
cells. No cytotoxicity was detected at 3b concentrations up to 1000 μM. Mechanistic studies demonstrated that
virus entry into the host cell was not affected, whereas viral RNA synthesis was strongly inhibited, as quantified
by real time RT-PCR. The addition of exogenous guanosine together with 3b rescued only partially the infectivity of DENV-2.
Conclusions: The acridone derivative 3b selectively inhibits the infection of Vero cells with the four DENV
serotypes without a direct interaction with the host cell or the virion but interfering specifically with the
intracellular virus multiplication. The mode of antiviral action for this acridone apparently involves the cellular
enzyme inosine-monophospahe dehydrogenase together with another still unidentified target related to DENV
RNA synthesis.
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The four serotypes of dengue virus (DENV-1 - DENV-4)
are the most important mosquito-borne human patho-
gens included in the family Flaviviridae. The World
Health Organization estimates that DENV infects annu-
ally 50 million people around the world causing a wide
range of clinical disease, from the benign and autolim-
ited dengue fever to the severe forms of dengue
hemorrhagic fever and dengue shock syndrome [1,2].
However, new appraisals indicate that apparent and in-
apparent DENV infections would reach the number of
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unless otherwise stated.sense single stranded RNA inserted in an icosahedral nu-
cleocapsid and surrounded by a lipid envelope. The gen-
ome is translated into three structural proteins (the
envelope E glycoprotein, the membrane M and the capsid
C proteins) and seven non-structural proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B and NS5).
No specific anti-DENV drugs or vaccines are currently
available. The present treatment for DENV infected pa-
tients consists only in supportive medical care directed
to reduce the symptoms and to improve survival in the
severe forms of disease. Given the worldwide expansion
of DENV reemergence in different geographical regions
and the consequent increase in at risk population, there
is an urgent need of effective compounds to control
morbidity and mortality caused by this flavivirus. To
date, several strategies have been intended for develop-
ment of anti-DENV agents, directed to block either aral. This is an Open Access article distributed under the terms of the Creative
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virus multiplication and/or pathogenesis [5,6]. Although
the estimated global prevalence of dengue is very high,
very few clinical trials have been performed. The can-
didate drugs just tested in humans include the lysoso-
motropic agent chloroquine [7] and the polymerase
inhibitor balapiravir [8], both without therapeutic effi-
cacy, whereas trials of lovastatin, a cholesterol-reducing
agent, and cellular glucosidase inhibitors are currently
underway [9,10].
As occurs with other RNA viruses, the inhibition of
intracellular DENV RNA synthesis has been one of the
most explored approaches for antiviral studies. The pro-
teins NS3 and NS5 are engaged in viral RNA replication:
the NS5 conserved protein has a methyltransferase activ-
ity in the N-terminal domain, involved in RNA cap for-
mation, and an RNA-dependent RNA polymerase in the
C-terminal domain [11,12], whereas the C-terminal por-
tion of NS3 comprises 5’RNA triphosphatase, RNA heli-
case and nucleoside triphosphatase activities [13]. Both
NS3 and NS5 have been structurally characterized and
are possible antiviral targets [12,14,15]. Furthermore, di-
verse compounds interacting with host cell components
participating in viral RNA replication or transcription,
like cellular proteins interacting with viral RNA or in-
volved in the de novo biosynthesis of purine or pyrimi-
dine nucleotides, have also been investigated [16].
Regarding viral RNA inhibition, acridones are a class
of heterocyclic compounds that have attracted attention
in recent years for their wide range of biological proper-
ties centered on the synthesis of nucleic acids, including
anti-cancer properties and inhibitory action against
DNA and RNA viruses [17-20]. In a previous screening
assay of antiviral activity against DENV-2 of a series of
N-substituted acridones, we identified a group of N-allyl
derivatives as effective virus inhibitors [21]. Here, the
antiviral activity and mode of action targeted to viral
RNA replication of one of the most active DENV-2
inhibitors, the 10-allyl-7-chloro-9(10H)-acridone desig-
nated 3b (Figure 1A), was further characterized.
Methods
Compounds
The acridone derivative 3b was synthesized as previously
described [21]. Stock solution at a concentration of
100 mM was prepared in dimethylsulfoxide. Ribavirin
(RIB) was purchased at Sigma-Aldrich and was also dis-
solved in dimethylsulfoxide.
Cells and viruses
Vero (African green monkey kidney) and HeLa (hu-
man cervical carcinoma) cells were grown in Eagle’s
minimum essential medium (MEM) (GIBCO) supple-
mented with 5% fetal bovine serum. For maintenancemedium, the serum concentration was reduced to
1.5%. The C6/36 mosquito cell line from Aedes albo-
pictus, adapted to grow at 33°C, was cultured in L-15
medium (Leibovitz) supplemented with 0.3% tryptose
phosphate broth, 0.02% glutamine, 1% MEM non-
essential amino acids solution and 10% fetal bovine
serum.
Virus stocks of DENV-1 strain Hawaii, DENV-2 strain
New Guinea C (NGC), DENV-3 strain H87 and DENV-
4 strain 8124 were prepared in C6/36 cells and titrated
by plaque formation in Vero cells.
Antiviral assay
Antiviral activity was determined by a virus yield inhib-
ition assay. Vero cells grown in 24-well plates were in-
fected at a multiplicity of infection (MOI) of 0.1 PFU/cell.
After 1 h at 37°C, cells were washed and refed with main-
tenance medium containing or not serial two-fold dilu-
tions of compound. After 48 h of incubation at 37°C,
extracellular DENV yields were determined by plaque
forming units (PFU) titration in Vero cells. In a similar
assay, we have previously determined that treatment with
medium containing dimethylsulfoxide 1:100–1:10000 (solv-
ent dilutions corresponding to the working solutions of
compound) did not affect DENV infectivity. The effective
concentration 50% (EC50) was calculated as the concen-
tration required to reduce virus yield by 50% in the
compound-treated cultures compared with untreated
ones using a non linear regression of dose response in-
hibition with GraphPad Prism software. All determina-
tions were performed thrice, and each time in duplicate.
Cell viability assay
Vero and HeLa cell cultures grown in 96-well plates (5 ×
104 cells/well) were exposed for 96 h to serial two-fold
compound dilutions, three wells for each concentration.
Then, viability was measured by the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT,
Sigma-Aldrich) method as previously described [22]. The
cytotoxic concentration 50% (CC50) is the compound con-
centration required to reduce the MTT signal by 50%
compared to untreated controls, calculated as mentioned
for EC50. All determinations were performed thrice and
each one in duplicate.
Cell protein synthesis
Vero cells were incubated in the presence or absence of
100 μM 3b during 48 h at 37°C. Then, cells were
washed with phosphate buffer and incubated in
methionine-cysteine-free medium in the presence or
absence of compound for 1 h, and then labelled by
addition of 100 μCi/ml of EXPRE35S-35S (NEN Dupont)
for 4 h. After labelling, cells were lysed in sample elec-
trophoresis buffer (5% sodium dodecyl sulfate, 2% 2-
Figure 1 Cytotoxicity and antiviral activity of 3b. (A) Chemical structure of compound 3b. (B) Vero cells were incubated for 96 h in the presence
of different concentrations of 3b and then cell viability was determined by MTT assay (■). Other set of cultures were infected with DENV-2 (MOI
0.1 PFU/cell) in the presence or absence of 3b and virus yields were determined at 48 h p.i. (□). (C) Effect of 3b on cell protein synthesis. Vero
cells were incubated for 48 h with or without 100 μM 3b. Then, cells were labeled with 100 μCi/ml EXPRE35S-35S for 4 h and polypeptides were
electrophoresed. (D) Vero cells were infected with DENV-1 (■), DENV-3(▲) or DENV-4 (Δ) at a MOI of 0.1 PFU/cell in the presence or absence of
3b and virus yields were determined at 48 h p.i. (E) Cytotoxicity (■) and antiviral activity (□) against DENV-2 (MOI 0.1 PFU/cell) were determined
in HeLa cells as in (B). In (B), (D) and (E) results are expressed as % cell viability or virus yield with respect to control without drug treatment and
represent the mean of three independent experiments ± standard deviation.
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blue in 0.0625 M Tris–HCl, pH 6.8). Cell lysates were son-
icated for 1 min, boiled during 2 min and loaded forelectrophoresis on 15% SDS-polyacrylamide gels (lysates
corresponding to 1.0 × 105 cells/well). Protein bands were
visualized by fluorography.
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Pretreatment of cells: Vero cells were pre-incubated with
maintenance medium containing or not 100 μM 3b for
2 h at 37°C. Then, cells were thoroughly washed with
medium and infected with DENV-2 (MOI of 0.1) in the
absence of compound. Virus yields were determined at
48 h p.i. by PFU. Pretreatment of virus: a DENV-2 sus-
pension (1 × 106 PFU/ml) was incubated in MEM con-
taining or not 100 μM 3b for 1.5 h at 37°C. Then,
samples were diluted and the remaining infectivity was
titrated by PFU. Treatment during virus infection: Vero
cells were infected with DENV-2 with DENV-2 and after
adsorption medium containing 3b was added and main-
tained during 48 h at 37°C, when virus yields were
determined.
Virus adsorption and internalization
For evaluation of virus adsorption, Vero cells grown in
coverslips were infected with DENV-2 (MOI 1 PFU/cell)
in the presence or absence of 100 μM 3b. After 15 min
adsorption at 4°C, cell monolayers were washed with
cold phosphate buffer and fixed in methanol for 15 min
at −20°C for cytoplasmic immunofluorescence. Indirect
staining was carried out by using mouse monoclonal
antibody against DENV E glycoprotein (Abcam) and
fluorescein isothiocyanate-labeled goat anti-mouse IgG
(Sigma-Aldrich). After a final washing with phosphate
buffer, cells were stained with Evans Blue and mounted
in a glycerol solution containing 1,4-diazabicyclo [2]
octane.
For virus internalization assay, Vero cells grown in
coverslips were infected with DENV-2 (MOI 1 PFU/cell).
After 1 h adsorption at 4°C, cells were washed with cold
phosphate buffer and incubated at 37°C for 1 h in
medium containing or not 100 μM 3b. Then, cells were
fixed in methanol and internalized viral protein was
stained for indirect immunofluorescence as above.
Expression of viral proteins
Vero cells grown in coverslips were infected with DENV-2
(MOI 1 PFU/cell) in the presence or absence of 100 μM
3b. At 48 h p.i., cells were fixed and processed for cyto-
plasmic immunofluorescence as above described.
Synthesis of viral RNA
Vero cells were infected with DENV-2 at a MOI of 1
PFU/cell and after adsorption cells were refed with
maintenance medium containing or not 100 μM 3b. At
8, 24 and 48 h p.i., total RNA was extracted by using
TRIZOL (Invitrogen Life Technologies) according to the
manufacturer’s instructions. Then, cDNA was generated
by using murine reverse transcriptase M-MLV (100 U/
μl, Invitrogen) and random primers. This cDNA wasamplified by real time PCR using SYBRGreen (Roche)
detection. The mix reaction volume was 25 μl including
2 μl of cDNA, DNA polymerase GoTaq (5 U/μl, Promega)
and specific primers to amplify the gene of NS1 protein
(the sense primer was 5’CGATCTCTCAGCCCCAGCCC
ACTGAGC3’ and the antisense, 5’CCATGTGTCATTG
AGTGCACTTTCTATCC3’). Real time PCR was carried
out with an initial incubation at 95°C during 3 min,
followed by 40 cycles of 15 s at 95°C, 1 min at 61°C and
30 s at 72°C and 10 min at 72°C. Amplification plots were
expressed as CT values to be analyzed with Opticon Moni-
tor 3.1 software to calculate the relative amounts of viral
RNA. The cellular gene actin was used as standard for
normalization.
Reversal by guanosine
To address the ability of guanosine to reverse the inhibi-
tory effect on virus infection, DENV-2 was adsorbed to
Vero cells at a MOI of 0.1 PFU/cell for 1 h. Then, cul-
tures were incubated with maintenance medium con-
taining a fixed concentration of 3b (100 μM) or ribavirin
(RIB) (200 μM) and variable concentrations of guanosine
(0–1000 μM). Other set of Vero cell cultures were in-
fected with DENV-2 as above and incubated with
medium containing only guanosine (0–1000 μM). For all
treatments, extracellular virus yields were determined
after 48 h of infection by PFU.
Molecular docking studies
Crystal structures of the proteins were obtained from
Protein Data Bank. In Discovery studio (DS) program,
proteins were modified by removing hetatoms from the
structures. Ligand structure was checked with Marvin-
Sketch and its geometry optimised by DS. Protein Data
Bank file formats of the proteins and mol2 or sd file for-
mats of the ligands were uploaded to all currently used
softwares.
The active sites of the enzymes were determined by
combining literature data with virtual screening observa-
tions. DS and Pymol were drived as virtual screening
tools.
Molegro Virtual Docker (MVD) and GOLD molecular
docking softwares were used together in a comparative
manner. The searching space was specified that includes
the active site properly. All explicit hydrogens were
added into the structures. MolDock Score were used in
MVD docking setup with the following settings: for the
local search, MolDock Simplex Evolution algorithm was
applied with a maximum of 2000 iterations per search.
Fifty independent docking runs were carried out. Posi-
tions of the hydrogens for any hydrogen donors (both in
3b and in the enzyme) were optimised. The Ignore Simi-
lar Poses option was used to avoid reporting to similar
poses. All poses returned from the runs were clustered
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terion and similar poses were removed (keeping the
best-scoring one). Different poses of the compounds
were ranked by their rerank scores and the best docked
conformation was selected. More negative score indi-
cates higher binding affinity. In Gold docking setup,
Gold Genetic Algorithm was used with the slow option.
ChemPLP (Piecewise Linear Potential) method was
chosen as the scoring function and ChemScore was the
rescoring function. Search options of Genetic Algorithm
were automatically configured by the programme.
Resulting poses were ranked by their PLR fitness func-
tions and Chemscore ΔG values. In GOLD higher fitness
score means better docked pose.
Statistical analyses
Statistical analyses were performed using GraphPad
Prism software. Comparison of means was tested by
one-way analysis of variance (ANOVA) with Dunnett’s
posttest. Statistical significance was defined as p < 0.05.
Three asterisks (***), P ≤ 0.001.
Results
Spectrum of anti-DENV activity
The antiviral activity of 3b against DENV-2 was evalu-
ated by a virus yield reduction assay in Vero cells. As
seen in Figure 2A, this compound exerted a dose-
dependent inhibition of virus multiplication, attaining aFigure 2 Effect of treatment of cells or virus with 3b before and
during infection. Pretreatment of cells: Vero cells were incubated
with maintenance medium containing or not 100 μM 3b for 2 h at
37°C, then compound was removed and cells were infected with
DENV-2. Virus yields were determined at 48 h p.i. Pretreatment of
virus: DENV-2 suspensions were incubated with MEM containing or
not 100 μM 3b for 1.5 h at 37°C and then remaining infectivity was
determined by plaque assay. Treatment during infection: Compound
was added to Vero cells after virus adsorption and maintained for
48 h at 37°C, when virus yields were determined. Results are
expressed as percent of remaining infectivity in compound-treated
samples compared to untreated ones. Each value is the mean of
triplicate assays ± standard deviation.reduction in DENV-2 yield relative to untreated infected
cultures higher than 90% in the range of concentrations
50–100 μM.
By contrast, no important cytotoxic effects were de-
tected by MTT method in Vero cell cultures after 96 h
of incubation with the compound (Figure 1B). Further-
more, the cell treatment with 3b up to a concentration
of 1 mM, highly exceeding the effective antiviral concen-
tration, almost did not alter Vero cell viability (data not
shown).
The influence of 3b on cell metabolism was further
studied by analyzing cell protein synthesis after com-
pound treatment. By radiolabeling of Vero cell cultures
in the presence or absence of 100 μM 3b and polypep-
tide detection by polyacrylamide-gel electrophoresis,
only minimal alterations in intensity levels for certain
protein bands were observed in acridone-treated cells in
comparison with untreated ones (Figure 1C). These re-
sults are consistent with the very weak reduction in cell
viability registered after treatment with 100 μM 3b as
shown by MTT assay in Figure 1B, confirming the lack
of undesirable effects of 3b on host cell and the selectiv-
ity of the observed anti-DENV activity.
It has been reported that the inhibitory effect against
DENV of some compounds may be variable according
to virus serotype [22-25]. Since all DENV serotypes co-
circulate simultaneously in several tropical and subtrop-
ical areas, the antiviral activity against the four DENV
serotypes was next evaluated by virus yield reduction
assay. A dose-dependent inhibition similar to that pre-
sented for DENV-2 was obtained with the other sero-
types (Figure 1D). The values of EC50 of 3b for all
serotypes, extrapolated from dose response curves, are
presented in Table 1. Although slight variations are ob-
served in antiviral susceptibility, the acridone exhibited a
good degree of effectiveness against the four DENV se-
rotypes, with selectivity indices (ratio between cytotox-
icity and antiviral activity) in the range > 36.9 - > 80.0,
values that warrant the potential perspectives of this type
of compound as anti-DENV agent. These results confirm
our previous report about screening of antiviral activity
with diverse classes of substituted acridones that showedTable 1 Antiviral activity profile of 3b against DENV
serotypes
DENV serotype EC50 (μM)
a SIb
DENV-1 26.7 ± 1.8 >37.3
DENV-2 13.5 ± 0.9 >74.1
DENV-3 27.1 ± 2.1 >36.9
DENV-4 12.5 ± 0.8 >80.0
aEffective concentration 50%: compound concentration required to reduce virus
yields at 48 h p.i. by 50%. Values are the mean from triplicate independent
tests ± standard deviation.
bSelectivity index: ratio CC50/EC50. The CC50 for 3b is > 1000 μM.
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types for other two different acridone derivatives [21].
The influence of the host cell on the antiviral inhib-
ition was also analyzed. In particular, human-derived
cells like the HeLa cell line was employed in the virus
yield inhibition assay. The sensitivity of HeLa cells to the
anti-DENV action of 3b was comparable to that ob-
served in Vero cells (Figure 1E). The EC50 against
DENV-2 in HeLa cells was 23.9 ± 2.5 μM and, since the
compound did not affect HeLa cell viability at concen-
trations up to 1000 μM as determined by MTT assay,
the SI in HeLa cells was > 41.7, in the order of anti-
DENV selectivity detected in Vero cells (Table 1).
Acridone has no inhibitory action by cell or virus
pretreatment
To characterize the mode of action of the acridone 3b
against DENV-2, we first investigated the possibility that
the compound acted directly on the cells to be infected,
inducing a cellular antiviral state, or directly on the
virus, leading to inactivation of virion infectivity. The pre-
incubation of Vero cells with 3b, followed by compound
removal and subsequent DENV-2 infection, did not pro-
duce any inhibition in virus yield at 48 h p.i. (Figure 2).
Similarly, the acridone was not effective in reducing virus
titer after 1 h of pre-incubation of a virus suspension with
compound.
Only when the acridone was added to cells simultan-
eously with virus, DENV-2 yield was significantly re-
duced as seen in Figure 2. Then, 3b failed either to
induce a refractory state by cell pretreatment or to
neutralize DENV-2, and the inhibitory effect was exclu-
sively exerted through a blockade in virus multiplication
during the course of infection.
Effects of acridone on DENV-2 entry, RNA synthesis and
protein expression
To understand the mechanism underlying acridone in-
hibition of DENV infection, we investigated the effect of
3b on different steps of the virus multiplication cycle.
The potent inhibition observed in experiments presented
in Figures 1 and 2 was always obtained in the absence of
compound during virus adsorption. The lack of effect of
3b on DENV-2 adsorption was confirmed by immuno-
fluorescent staining of bound viral proteins after 1 h of
incubation at 4°C (Figure 3A). Next, the action of 3b on
DENV-2 internalization was studied. DENV-2 was
adsorbed to Vero cells for 1 h at 4°C, then the com-
pound was added and temperature of incubation was
immediately raised to 37°C to allow virus internalization.
Under these treatment conditions, the internalized
DENV-2 proteins after 1 h at 37°C detected by immuno-
fluorescence staining was similar in compound-treated
and –untreated cells (Figure 3B).Afterwards, viral macromolecular synthesis was evalu-
ated. Real time PCR was employed to measure intracel-
lular viral RNA at 8, 24 and 48 h p.i. in DENV-2
infected Vero cells in the presence or absence of
100 μM 3b. In the first 8 h p.i., no significant difference
in viral RNA profile was detected between 3b-treated
and untreated cells (Figure 3C), supporting that the com-
pound did not block the initial events of DENV multipli-
cation cycle. By contrast, data shown in Figure 3C show
that acridone inhibited viral RNA synthesis by 40% at
24 h p.i. and about 80% inhibition in DENV-2 RNA accu-
mulation was displayed at 48 h p.i. The differences ob-
served in RNA inhibitory effect between early and later
times may be indicative of a very low amount of viral
RNA at 8 h p.i. that is not enough to visualize an inhib-
ition in the presence of the drug. When incubation time
is prolonged to 24–48 h, the amount of viral RNA in the
cells allows the detection of a significative reduction in
the presence of 3b.
The failure on RNA synthesis was also corroborated by
analyzing the effect of 3b on the expression of DENV-2
proteins, determined by indirect immunofluorescence
staining of E viral glycoprotein. A correlation between the
effects of 3b on DENV-2 RNA accumulation and protein
expression in infected cells was observed with a drastic re-
duction at 48 h p.i. in the number of cells expressing
DENV-2 protein as well as in the intensitity of cytoplasmic
immunofluorescence in the few positive cells (Figure 3D).
Reversal by guanosine on DENV infectivity
Acridone-based compounds have been reported to be
potent and uncompetitive inosine monophosphate de-
hydrogenase (IMPDH) inhibitors [26]. IMPDH is a key
enzyme responsible for catalyzing the conversion of in-
osine 5’-monophosphate to xanthosine 5’-monopho-
sphate, a rate-limiting step for intracellular de novo
synthesis of guanosine nucleotides.
To explore whether the antiviral activity of 3b might
be due to GTP pool reduction, DENV-2 infected Vero
cells were incubated with maintenance medium contain-
ing 3b, in the presence or absence of exogenous guano-
sine. As control RIB, a compound with reported
inhibitory activity against IMPDH [27,28], was simultan-
eously tested against DENV infection in the same condi-
tions. The reversal assay was performed with a fixed
concentration of each inhibitor that reduced virus titer
by almost 3 log (Figure 4), and increasing concentrations
of guanosine. The addition of exogenous guanosine res-
cued the infectivity of DENV in 3b-treated cells in a
dose-dependent manner, but the reversal was partial as
reflected in PFU levels: virus yields were reduced from
2.85 × 104 PFU/ml in the control infected cells to 7.0 ×
102 PFU/ml in 3b-treated cells, and the simultaneous
treatment with 3b and 1000 μM guanosine increased the
Figure 3 Effect of 3b on DENV-2 entry, RNA synthesis and protein expression. (A) Vero cells were infected with DENV-2 in the absence or
presence of 100 μM 3b. After 15 min adsorption at 4°C indirect immunofluorescence staining of E glycoprotein was performed by using mouse
monoclonal antibody against DENV E glycoprotein and fluorescein isothiocyanate-labeled goat anti-mouse IgG. Cells were stained with Evans
blue. Magnification: 1000X. (B) DENV-2 was adsorbed to Vero cells for 1 h at 4°C adsorption. Then, cells were incubated at 37°C for 1 h in medium
containing or not 100 μM 3b, and thereafter cells were stained for indirect immunofluorescence as above. Magnification: 400X. (C) Vero cells were
infected with DENV-2 and incubated for 8, 24 and 48 h in the absence or presence of 100 μM 3b. At each time point, total RNA was extracted
and cDNA was synthesized with random primers. These cDNAs were amplified by real time PCR using specific primers to amplify the ns1 gene,
and cellular actin was used for normalization. Results are expressed as % inhibition DENV-2 RNA level respect to viral control. (D) Vero cells were
infected with DENV-2 in the absence (virus control VC) or presence (3b) of 100 μM 3b. CC: cell control. At 48 h p.i. indirect immunofluorescence
staining of E glycoprotein was performed as in (A). Magnification: 400X.
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was recovered but there was still a 1.44 log of viral
inhibition in comparison to untreated infected cells
(Figure 4A). On the other hand, the guanosine reversal
for RIB was more complete with 2 log of infectivity re-
covered, and only 0.7 log of remaining viral yield inhib-
ition (Figure 4B). To discard any benefitial effect of
guanosine on DENV-2 replication and assess that the in-
creased virus yields shown in Figure 4A and B are due
to reversal of inhibition, Vero cells infected with DENV-
2 were also incubated with different concentrations of
guanosine in the absence of 3b or RIB. As shown inFigure 4C, the treatment of infected cells with guanosine
alone did not alter virus yield.
Docking studies
In order to explore if an interaction is possible at the
molecular level, an extensive docking modeling was per-
formed between the compound 3b and the postulated
target protein IMPDH. The 3D structure of human
IMPHD was obtained from Protein Data Bank (Acces-
sion Number: 1NF7). Molegro and GOLD molecular
docking softwares were used together for effective pose
prediction and virtual screening. For determining the
Figure 4 Reversal of inhibition by exogenous guanosine. Vero cells
were infected with DENV-2 and treated with 100 μM 3b (A) or
200 μM RIB (B) in the presence or absence of different guanosine
concentrations. Other set of cultures were infected with DENV-2 and
incubated with different concentrations of guanosine alone (C). After
48 h, extracellular virus yields were determined by plaque formation.
Each value is the mean of triplicate assays ± standard deviation.
(***), P ≤ 0.001.
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ChemPLP fitness score were used. Opposite of the rerank
scoring, higher ChemPLP fitness score means betterdocked pose. Comparative docking results showed that
the compound 3b occupied the active site of IMPHD with
a rerank score of −80.6446 and ChemPLP score of
51.0029, Chemscore ΔG of −25.0379. Two hydrogen bond
interactions were identified with the backbone amino acid
residues SER327 and GLY328. Moreover, 26 hydrophobic
interactions with 11 residues including active site -
CYS331- were observed (Figure 5A).
Next we analyzed how 3b binds to native ligand’s
interaction sites within the enzyme by using Molegro.
Nicotinamide adenine dinucleotide (NAD) and inosine
monophosphate (IMP) are chemically active native li-
gands of IMPDH which is an enzyme that catalyzes the
NAD-dependent oxidation of IMP [29,30]. Redocking
was applied to NAD and IMP for fair and accurate com-
parison. Complex form of IMPHD bound to its native li-
gands is stored in Protein Data Bank (Accession
Number: 1NFB). After determining the residues which
interact with NAD and IMP separately, ligands were re-
moved from the 1NFB structure. Then NAD and IMP
were docked back into the protein. 3b-IMPHD docking
was done by targeting the interaction regions of natural
substrates.
It is known from the crystallographic studies that
NAD binding site includes 11 structural amino acids
(Risal D, Strickler MD, Goldstein BM, Crystal structure
of human inosine monophosphate dehydrogenase type II
complexed with the MPA/NAD analog C2-MAD, in
preparation) (Figure 5B). Redocking of NAD gave
−117.426 rerank score, conversely, docking of 3b to this
NAD binding site gave −67.4364 rerank score. Relatively
low binding score of 3b revealed that this site does not
fit for it (Figure 5C). As for IMP, the substrate binds to
the enzyme through CYS331 and the other 11 amino
acids (Figure 5D). IMP’s docking back into IMPHD gave
score of −112.119. When the compound 3b was docked
in the IMP activity region, it made a hydrogen bond with
the side chain residue SER68 by resulting rerank score
of −82.2138 (Figure 5E). Then, the results implied that
3b showed higher binding affinity to IMP activity site
than NAD activity site.
In addition to 3b-NAD/IMP activity site interaction
analysis, we investigated 3b interactions with the inhibi-
tory regions of two IMPDH antagonists: RIB monopho-
sphate and C2-Mycophenolic Adenine Dinucleotide
(MYD). RIB monophosphate and MYD show their an-
tagonistic activity by blocking access to active site of
IMPHD. Following the previous part’s method, the pos-
ition of 3b when it interacts with each binding region of
those two inhibitors was figured out. The 3D structure
of IMPHD- RIB monophosphate, MYD complex was ob-
tained from Protein Data Bank (Accession number:
1NF7). As presented in the previous crystallographic
study, RIB monophosphate and MYD bind to their
Figure 5 Docking modeling between the compound 3b and the postulated target protein IMPDH. (A) 3b binds to the active site of the IMPHD
enzyme through 2 hydrogen bonds and hydrophobic interaction. (B) IMP interaction cavity consists of SER68, MET70, GLY328, SER329, ILE330,
CYS331, GLU335, ASP364, GLY365, GLY366, GLY387, SER388. (C) 3b made a hydrogen bond with SER68 and hydrophobic interactions with SER68,
MET70, ASP274, SER275, SER276, ASN303, ARG322, GLY324, MET325, SER327, GLY328, SER329, GLU335, ASP364, GLY365. (D) NAD interaction
pocket residues are THR45, THR252, HIS253, ASP274, SER275, SER276, PHE282, ASN303, ARG322, HIS466, GLN469. (E) Two hydrogen bonds existed
between 3b and ASN303, ARG322. 3b also made hydrophobic interactions with SER276, ASN303, ARG322, MET325, GLY326, CYS331, ILE332,
GLN334, LEU337. (F) RIB binding site includes SER68, MET70, ARG322, GLY328, SER329, ILE330, CYS331, ASP364, GLY365, GLY366, GLY387, SER388,
TYR411, GLY413, MET414, GLY415, GLN441. (G) 3b made hydrogen bonds with SER327, GLY328 and hydrophobic interactions with PRO69, MET70,
SER275, ASN303, ARG322, GLY324, GLY326, SER327, GLY328, ASP364, GLY365.(H) HIS253, ASP274, SER275, SER276, PHE282, ASN303, ARG322,
GLY324, MET325, GLY326, CYS331, THR333 involves in MYD activity cavity. (I) 3b made hydrophobic interactions with ASP274, SER275, SER276,
ASN303, GLY324, MET325, GLY326, SER327, GLY328, ASP364.
Mazzucco et al. Journal of Biomedical Science  (2015) 22:29 Page 9 of 12inhibitory pockets by making hydrogen bonds and
hydrophobic interactions (Risal D, Strickler MD, Gold-
stein BM, The conformation of NAD bound to human
inosine monophosphate dehydrogenase type II, in prep-
aration) (Figure 5 F,H). At first, they were docked back
into their pockets. Best-fitting poses’ rerank scores were
−116.695 for RIB monophosphate and −130.851for
MYD. Later, 3b was docked into each drug’s inhibitory
pocket. 3b presented high affinity to RIB monopho-
sphate binding region by resulting rerank score of82.2913. (Figure 5G). In contrast, it showed low affinity
to MYD inhibitory cavity (Figure 5I).
Discussion and conclusions
A preliminary structure-activity analysis with diverse
substituted acridones showed that certain N-allyl acri-
done derivatives exerted antiviral activity against the
hemorrhagic fever causing viruses DENV and Junin virus
(JUNV), agent of Argentine hemorrhagic fever [21]. In
particular, the halogen substituents in the acridone
Mazzucco et al. Journal of Biomedical Science  (2015) 22:29 Page 10 of 12heterocyclic ring were found associated to reduced cyto-
toxicity and increased antiviral effects. Two 6-chloro
derivatives, the 10-allyl-6-chloro-9(10H)-acridone and
10-allyl-6-chloro-4-methoxy-9(10H)-acridone, designated
3c and 3f, respectively, and one 7-chloro derivative, the
10-allyl-7-chloro-9(10H)-acridone or 3b, were potent in-
hibitors of DENV-2 and JUNV infection at noncytotoxic
concentrations [21]. In the present study, the anti-DENV
activity of 3b was pursued and the inhibition of the
in vitro DENV infection without a direct interaction with
the host cell or the virion was demonstrated. Furthermore,
the antiviral effectiveness of 3b appeared to be ascribed to
an interference with viral RNA synthesis.
Natural and synthetic acridone-based substances have
been known as multi-targeted agents with a wide
spectrum of biomedical potential [17,19]. In particular,
different acridone derivatives have been recently studied
as potential inhibitors of other members of Flaviviridae,
such as bovine viral diarrhea virus [31] and hepatitis C
virus [32-34], with very promising perspectives. Acri-
dones affected the functionality of viral RNA in infec-
tions with both flaviviruses. The inhibition of hepatitis C
virus enzymes like RNA helicase and RNA polymerase
has been reported for a group of N-substituted acridone-
4-carboxamides as well as the ability of these compounds
for RNA intercalation, probably leading to the disruption
of the interaction between the enzyme and the modified
nucleic acid [34]. Then, the possibility of multiple targets
to block viral RNA synthesis was suggested by the
authors.
The antiviral activity of 3b appears also related to inhib-
ition of viral RNA synthesis as determined by real time
PCR but the molecular mechanism has not been yet fully
elucidated. The strong inhibition observed in DENV-2 in-
fection may be partially restored by the simultaneous
addition of guanosine together with the acridone, indicat-
ing a possible involvement of the cellular enzyme IMPDH
as a potential target of this compound. This enzyme is an
interesting host factor to be considered for wide spectrum
antiviral chemotherapy [35]. In recent years, the targetingA B
Figure 6 Prediction affinity about 3b-IMPHD interaction (A) Binding of 3b
inhibitory site. (C) Binding of 3b to IMP activity site.of host functions essential for virus replication has
regained interest respect to the direct-acting antiviral
agents. Besides the certain possibility to develop com-
pounds active against a broad spectrum of viruses, the
cell-based approach is expected to reduce the chances for
emergence of drug-resistant viral variants. The disadvan-
tage of this strategy is the higher potential for cell toxicity
and undesirable effects, but it is not a drawback for acute
diseases like dengue fever or dengue hemorrhagic fever
that require short time of treatment. Furthermore, the tox-
icity of cellular protein-targeted compounds may be vari-
able according to the compound design. The main
challenge is to get an inhibitor with higher specificity to
block viral infection in comparison to cell viability, as ap-
pears to be for acridone 3b from data shown in Figure 1B.
In particular, several IMPDH inhibitors with in vitro anti-
DENV effectiveness in different mammalian cells have
been reported, including well-characterized drugs such as
RIB and mycophenolic acid [27,36] and also diverse clas-
ses of novel heterocyclic molecules [37-39]. Similarly, the
cellular enzyme dihydroorotate dehydrogenase (DHODH),
that is required for de novo pyrimidine biosynthesis, was
also tested in recent studies as a novel and effective host-
dependent target against DENV infection [40,41].
The molecular docking studies performed provide use-
ful information about 3b-IMPHD interaction. The bind-
ing orientation of 3b to human IMPHD was found in
order to predict the affinity and activity of the com-
pound. As the docking results presented, 3b showed the
best-fit orientation when it was docked into active site,
IMP and RIB monophosphate binding site of IMPHD
(Figure 6).
A probable disadvantage to face for the in vivo efficacy
of compounds targeting enzymes involved in purine or
pyrimidine biosynthesis may be the presence of exogen-
ous nucleotides in plasma that could be taken by the cell
and reverse the inhibitory activity. However, this issue
must be analyzed in each particular situation considering
the ability of any compound to overcome this inconveni-
ence. For example, it is crucial the concentration ofC
to IMPDH active site. (B) Binding of 3b to RIB monophosphate
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the inhibitory activity, a parameter that is not equivalent
for all compounds affecting nucleotide biosyntesis. In
addition it is also crucial the plasma binding activity of
the inhibitor because it may be determinant for the
plasma concentration of free compound to surpass the
effect of external nucleotide supplementation [41]. Ac-
cordingly, the antiviral in vivo evaluation in animal
models of IMPDH or DHODH inhibitors has reported
variable results. Leflunomide and a thiophene-2-carboxylic
acid derivative, two DHODH inhibitors, were effective
against respiratory syncytial virus infection of cotton rats
and cytomegalovirus infection of mice, respectively
[42,43], whereas the DHODH inhibitor designated NITD-
982 showed in vitro potency against DENV-2 but was in-
active in the AG129 mouse model [41]. Recently, the
chemical inhibition with mycophenolic acid or the deple-
tion mediated by RNA interference of IMPDH was found
effective to suppress in vivo DENV infection of Aedes
aegypti mosquitoes, an interesting strategy for blockade in
DENV transmission from vector to human and control of
virus dissemination [44].
In our case, there is an incomplete recovery of DENV-
2 infectivity by the presence of exogenous guanosine.
Consequently, more than one target related to DENV
RNA synthesis appeared responsible of the antiviral
activity of 3b, as above commented for other acri-
dones and flaviviruses. A similar partial participation
of IMPDH has also been reported for the antiviral
mechanism of other N-substituted acridone derivative, the
compound 10-allyl-6-chloro-4-methoxy-9(10H)-acridone,
against JUNV [45]. Since this last drug is also inhibitory
of DENV infection [21], the participation of cellular
IMPDH in the antiviral activity of these heterocyclic
compounds supports the wide spectrum of effectiveness
of diverse acridones against unrelated viruses, like JUNV
and DENV.
In conclusion, in the present study we demonstrated
that the acridone derivative 3b selectively inhibits the
in vitro infection with the four DENV serotypes without
a direct interaction with the host cell or the virion but
interfering specifically with the intracellular virus
multiplication. The cellular enzyme IMPDH appears to
be partially involved in anti-DENV activity of acridone,
but other unidentified target affecting viral RNA syn-
thesis must also be active to accomplish for the virus
yield inhibition produced by the drug, suggesting a dual
mechanism of antiviral action. The N-allyl acridones
are broad spectrum antiviral agents that represent a
very promising tool for management of hemorrhagic
fever-causing viruses lacking of specific chemotherapy.
The inhibitory effectiveness of acridones against DENV
and JUNV merits further testing of these compounds
with other medically relevant RNA viruses.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MBM, ACC: performed the virological experiments and analyzed the data;
MF, NBD: Designed and performed the chemical synthesis of compound;
LBT: designed the study and analyzed the data; SV: performed docking
studies; EBD, CCG: designed the study, analyzed the data and wrote the
manuscript. All authors read and approved the final manuscript.
Acknowledgments
Research was supported by grants from Agencia Nacional de Promoción
Científica y Tecnológica, Consejo Nacional de Investigaciones Científicas y
Técnicas (CONICET) and Universidad de Buenos Aires (UBA), Argentina. E.B.D.,
C.C.G., L.B.T. and N.B.D. are members of Research Career from CONICET.
The authors also acknowledge the critical review by Prof. Erman Burak.
Author details
1Laboratorio de Virología, Departamento de Química Biológica, Facultad de
Ciencias Exactas y Naturales, UBA, Ciudad Universitaria, Piso 4, Buenos Aires,
Pabellón 1428, Argentina. 2Graduate School of Science and Engineering, Koc
University, Rumelifener yolu, Istanbul, Sarıyer 34450, Turke.
3IQUIBICEN-Consejo Nacional de Investigaciones Científicas y Técnicas
(CONICET), Buenos Aires, Argentina. 4CIHIDECAR (CONICET), Departamento
de Química Orgánica, Facultad de Ciencias Exactas y Naturales, UBA, Ciudad
Universitaria, Pabellón 2, Piso 3, Buenos Aires 1428, Argentina. 5Present
address: Laboratorio de Reproducción y Metabolismo, Facultad de Medicina,
CEFYBO-CONICET, UBA, Buenos Aires 1121, Argentina. 6Present address:
Fundación Infant, Buenos Aires 1406, Argentina.
Received: 20 August 2014 Accepted: 8 April 2015
References
1. Guzmán MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al.
Dengue: a continuing global threat. Nat Rev Microbiol. 2010;8:S7–S16.
2. Kyle JL, Harris E. Global spread and persistence of dengue. Annu Rev
Microbiol. 2008;62:71–92.
3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The
global distribution and burden of dengue. Nature. 2013;496:504–7.
4. Mitka M. Dengue more prevalent than previously thought. JAMA.
2013;309:1882.
5. Noble CG, Chen Y-L, Dong H, Gu F, Lim SP, Schul W, et al. Strategies for
development of dengue virus inhibitors. Antiviral Res. 2010;85:450–62.
6. Sampath A, Padmanabhan R. Molecular targets for flavivirus drug discovery.
Antiviral Res. 2009;81:6–15.
7. Borges MC, Castro LA, Da Fonseca BA. Chloroquine use improves dengue-related
symptoms. Mem Inst Oswaldo Cruz. 2013;108:596–9.
8. Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh Hle A, Farrar J, et al. A
randomized, double-blind placebo controlled trial of balapiravir, a polymerase
inhibitor, in adult dengue patients. J Infect Dis. 2013;207:1442–50.
9. Whitehorn J, Van Vinh CN, Truong NT, Tai LT, Van Hao N, Hien TT, et al.
Lovastatin for adult patients with dengue: protocol for a randomized
controlled trial. Trials. 2012;13:203.
10. Chang J, Block TM, Guo J-T. Antiviral therapies targeting host ER alpha-
glucosidases: Current status and future directions. Antiviral Res.
2013;99:251–60.
11. Egloff MP, Decroly E, Malet H, Selisko B, Benarroch D, Ferron F, et al.
Structural and functional analysis of methylation and 5’-RNA sequence
requirements of short capped RNAs by the methyltransferase domain of
dengue virus NS5. J Mol Biol. 2007;372:723–36.
12. Malet H, Massé N, Selisko B, Romette J-L, Alvarez K, Guillemot JC, et al. The
flavivirus polymerase as a target for drug discovery. Antiviral Res.
2008;80:23–35.
13. Li H, Clum SR, You S, Ebner KE, Padmanabhan R. The serine protease and
RNA-stimulated nucleoside triphosphatase and RNA helicase functional
domains of dengue virus type 2 NS3 converge within a region of 20 amino
acids. J Virol. 1999;73:3108–16.
14. Dong H, Zhang B, Shi P-Y. Flavivirus methyltransferase: a novel antiviral
target. Antiviral Res. 2008;80:1–10.
Mazzucco et al. Journal of Biomedical Science  (2015) 22:29 Page 12 of 1215. Lescar J, Dahai L, Xu T, Sampath A, Lim SP, Canard B, et al. Towards the
design of antiviral inhibitors against flaviviruses: the case for the
multifunctional NS3 protein from Dengue virus as a target. Antiviral Res.
2008;80:94–101.
16. Pastorino B, Nougairede A, Wurtz N, Gould E, De Lamballeire X. Role of host
cell factors in flavivirus infection: Implications for pathogenesis and
development of antiviral drugs. Antiviral Res. 2010;87:281–94.
17. Belmont P, Bosson J, Godet T, Tiano M. Acridine and acridone derivatives,
anticancer properties and synthetic methods: where are we now?
Anticancer Agents Med Chem. 2007;7:139–69.
18. Bastow KF. New acridone inhibitors of human herpes virus replication. Curr
Drug Targets: Infect Disord. 2004;4:323–30.
19. Sepúlveda CS, Fascio ML, García CC, D’Accorso NB, Damonte EB. Acridones
as antiviral agents: synthesis, chemical and biological properties. Curr Med
Chem. 2013;20:2402–14.
20. Sasvari Z, Bach S, Blondel M, Nagy PD. Inhibition of RNA recruitment and
replication of an RNA virus by acridine derivatives with known anti-prion
activities. PLoS One. 2009;4, e7376.
21. Sepúlveda CS, Fascio ML, Mazzucco MB, Docampo Palacios ML, Pellón RF,
García CC, et al. Synthesis and evaluation of N-substituted acridones as
antiviral agents againts haemorrhagic fever viruses. Antivir Chem
Chemother. 2008;19:41–7.
22. Talarico LB, Damonte EB. Interference in dengue virus adsorption and
uncoating by carrageenans. Virology. 2007;363:473–85.
23. Hidari KI, Takahashi N, Arihara M, Nagaoka M, Morita K, Suzuki T. Structure
and anti-dengue virus activity of sulfated polysaccharide from a marine alga.
Biochem Biophys Res Commun. 2008;376:91–5.
24. Kaptein SJF, De Burghgraeve T, Froeyen M, Pastorino B, Alen MMF,
Mondotte JA, et al. A derivative of the antibiotic doxorubicin is a selective
inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob
Ag Chemother. 2010;54:5269–80.
25. Talarico LB, Pujol CA, Zibetti RG, Faria PC, Noseda MD, Duarte ME, et al. The
antiviral activity of sulfated polysaccharides against dengue virus is
dependent on virus serotype and host cell. Antiviral Res. 2005;66:103–10.
26. Watterson SH, Chen P, Zhao Y, Gu HH, Dhar TG, Xiao Z, et al. Acridone-
based inhibitors of inosine 5’-monophosphate dehydrogenase: discovery
and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)
pyridine-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroxyacridine-3-carboxamide
(BMS-566419). J Med Chem. 2007;50:3730–42.
27. Takhampunya R, Ubol S, Houng H-S, Cameron CE, Padmanabhan R. Inhibition
of dengue virus replication by mycophenolic acid and ribavirin. J Gen Virol.
2006;87:1947–52.
28. Leyssen P, Balzarini J, De Clercq E, Neyts J. The predominant mechanism by
which ribavirin exerts its antiviral activity in vitro against flaviviruses and
paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol.
2005;79:1943–7.
29. Crabtree GW, Henderson JF. Rate-limiting steps in the interconversion of
purine ribonucleotides in Ehrlich ascites tumor cells in vitro. Cancer Res.
1971;31:985–91.
30. Jackson RC, Weber G, Morris HP. IMP dehydrogenase, an enzyme linked
with proliferation and malignancy. Nature. 1975;256:331–3.
31. Tabarrini O, Manfroni G, Fravolini A, Cecchetti V, Sabatini S, De Clercq E,
et al. Synthesis and anti-BVDV activity of acridones as new potential antiviral
agents. J Med Chem. 2006;49:2621–7.
32. Manfroni G, Paeshuyse J, Massari S, Zanoli S, Gatto B, Maga G, et al.
Inhibition of subgenomic hepatitis C virus RNA replication by acridone
derivatives: identification of an NS3 helicase inhibitor. J Med Chem.
2009;52:3354–65.
33. Stankiewicz-Drogon A, Palchykovska LG, Kostina VG, Alexeeva IV, Shved AD,
Boguszewska-Chachulska AM. New acridone-4-carboxylic acid derivatives as
potential inhibitors of Hepatitis C virus infection. Bioorg Med Chem.
2008;16:8846–52.
34. Stankiewicz-Drogon A, Dorner B, Erker T, Boguszewska-Chachulska AM.
Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which
efficiently and specifically inhibit subgenomic HCV replication. J Med
Chem. 2010;53:3117–26.
35. Nair V, Shu Q. Inosine monophosphate dehydrogenase as a probe in
antiviral drug discovery. Antiviral Chem Chemother. 2007;18:245–58.
36. Diamond MS, Zachariah M, Harris E. Mycophenolic acid inhibits dengue
virus infection by preventing replication of viral RNA. Virology.
2002;304:211–21.37. Markland W, McQuaid TJ, Jain J, Kwong AD. Broad-spectrum antiviral activity
of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and
demonstration of antiviral additivity with alpha interferon. Antimicrob
Agents Chemother. 2000;44:859–66.
38. Nair V, Chi G, Shu Q, Julander J, Smee DF. A heterocyclic molecule with
significant activity against dengue virus. Bioorg Med Chem Lett.
2009;19:1425–7.
39. McDowell M, Gonzales SR, Kumarapperuma SC, Jeselnik M, Arterburn JB,
Hanley KA. A novel nucleoside analog, 1-β-D-ribofuranosyl-3-ehynyl-[1,2,4]
triazole (ETAR) exhibits efficacy against a broad range of flaviviruses in vitro.
Antiviral Res. 2010;87:78–80.
40. Qing M, Zou G, Wang Q-Y, Xu HY, Dong H, Yuan Z, et al. Characterization of
dengue virus resistance to brequinar in cell culture. Antimicrob Agents
Chemother. 2010;54:3683–95.
41. Wang Q-Y, Bushell S, Qing M, Xu HY, Bonavia A, Nunes S, et al. Inhibition of
dengue virus through suppression of host pyrimidine biosynthesis. J Virol.
2011;85:6548–56.
42. Dunn MC, Knight DA, Waldman WJ. Inhibition of respiratory syncytial virus
in vitro and in vivo by the immunosuppresive agent leflunomide. Antivir
Ther. 2011;16:309–17.
43. Marschall M, Niemann I, Kosulin K, Bootz A, Wagner S, Dobner T, et al.
Assessment of drug candidates for broad-spectrum antiviral therapy targeting
cellular pyrimidine biosynthesis. Antiviral Res. 2013;100:640–8.
44. Kang S, Shields AR, Jupatanakul N, Dimopoulos G. Suppressing dengue-2
infection by chemical inhibition of Aedes aegypti host factors. PLoS Negl
Trop Dis. 2014;8, e3084.
45. Sepúlveda CS, García CC, Fascio ML, D’Accorso NB, Docampo Palacios ML,
Pellón RF, et al. Inhibition of Junín virus RNA synthesis by an antiviral
acridone derivative. Antiviral Res. 2012;93:16–22.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
